Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 28 of 28 publications.

Brufsky A, Kwan ML, Sandin R, Stergiopoulos S, Karanth S, Cha-Silva AS, Makari D, Goyal RK. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2− and HER2+ metastatic breast cancer. Breast Cancer Res Treat. 2024 Nov;208(2):223-35. doi: 10.1007/s10549-024-07469-6

Goyal RK, Zhang J, Davis KL, Sluga-O'Callaghan M, Kaufman PA. Real-world treatment patterns and clinical outcomes in patients treated with eribulin after prior phosphoinositide 3-kinase inhibitor treatment for metastatic breast cancer. Breast Cancer Res Treat. 2024 May;205(1):201-10. doi: 10.1007/s10549-023-07080-1

DiBenedetti D, Kosa K, Waters HC, Oberdhan D. Understanding patients' experiences with borderline personality disorder: qualitative interviews. Neuropsychiatr Dis Treat. 2023 Oct 9;19:2115-25. doi: 10.2147/NDT.S423882

Wilson A, Kragh N, DiBenedetti D, Pan-Petesch B, Wynn T, Neme D, Willemze A. Patient experience with efanesoctocog alfa: results from the XTEND-1 phase 3 clinical trial exit interviews in patients with severe haemophilia A. Poster presented at the 16th Annual Congress of European Association for Haemophilia and Allied Disorders 2023; February 7, 2023. Manchester, England. [abstract] Haematologica. 2023 Feb 5; 29(S1):137-8. doi: 10.1111/hae.14715

Goyal RK, Holmes HM, Chen H, Abughosh S, Candrilli SD, Johnson ML. Impact of CDK4/6 inhibitors on chemotherapy utilization in earlier therapy lines for HR+/HER2- metastatic breast cancer in the United States. Breast Cancer Res Treat. 2023 Feb;198(1):159-66. doi: 10.1007/s10549-022-06845-4

Perez EA, Dang C, Lee C, Singh J, Wang K, Layton JB, Gilsenan A, Hackshaw MD, Cortes J. Incidence of adverse events with therapies targeting HER2-positive metastatic breast cancer: a literature review. Breast Cancer Res Treat. 2022 Jul;194(1):1-11. doi: 10.1007/s10549-021-06469-0

Richardson D, Zhan L, Mahtani R, McRoy L, Mitra D, Reynolds M, Odom D, Hollis K, Kaye JA, Jones C, Hargis J. A prospective observational study of patient-reported functioning and quality of life in advanced and metastatic breast cancer utilizing a novel mobile application. Breast Cancer Res Treat. 2021 May;187(1):113-24. doi: 10.1007/s10549-020-06082-7

Stenehjem DD, Telford C, Unni SK, Bauer H, Sainski A, Deka R, Schauerhamer MB, Ye X, Tak CR, Ma J, Dalvi TB, Gutierrez L, Kaye JA, Tyczynski JE, Brixner DI, Biskupiak JE. BRCA testing and outcomes in women with breast cancer. Breast Cancer Res Treat. 2021 Apr;186(3):839-50. doi: 10.1007/s10549-020-06038-x

Hackshaw MD, Danysh HE, Singh J, Ritchey ME, Ladner A, Taitt C, Camidge DR, Powell CA. Incidence of pneumonitis/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2020 Jun 26;183(1):23-39. doi: 10.1007/s10549-020-05754-8

Imagawa H, Nagar SP, Montgomery W, Nakamura T, Sato M, Davis KL. Treatment patterns, health care resource utilization, and costs in Japanese adults with attention-deficit hyperactivity disorder treated with atomoxetine. Neuropsychiatr Dis Treat. 2018 Feb 22;14:611-21. doi: 10.2147/NDT.S150261

Liede A, Mansfield CA, Metcalfe KA, Price MA, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Snyder C, Lynch HT, Friedman S, Amelio J, Posner J, Narod SA, Lindeman GJ, Evans DG. Preferences for breast cancer risk reduction among BRCA1/BRCA2 mutation carriers: a discrete-choice experiment. Breast Cancer Res Treat. 2017 Sep;165(2):433-44. doi: 10.1007/s10549-017-4332-3.

Novick D, Montgomery W, Aguado J, Peng XM, Haro JM. Impact of anxiety symptoms on outcomes of depression: an observational study in Asian patients. Neuropsychiatr Dis Treat. 2016 Apr 11;12:795-800. doi: 10.2147/NDT.S90134

Dine JL, O'Sullivan CC, Voeller D, Greer YE, Chavez KJ, Conway CM, Sinclair S, Stone B, Amiri-Kordestani L, Merchant AS, Hewitt SM, Steinberg SM, Swain SM, Lipkowitz S. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat. 2016 Jan;155(2):235-51. doi: 10.1007/s10549-015-3673-z.

Coles T, Coon C, DeMuro C, McLeod LD, Gnanasakthy A. Psychometric evaluation of the Sheehan Disability Scale in adult patients with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2014 May 19;10:887-95. doi: 10.2147/NDT.S55220. eCollection 2014

Twiss J, McKenna S, Crawford S, Wilburn J, Loth K. Are transfusions for Myelodysplasia (MDS) an acceptable treatment to patients? Poster presented at the 17th Congress of European Hematology Association; June 2012. Amsterdam, the Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(S1):693.

Kiladjian JJ, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy R, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi A, Harrison C. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, the Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):154-5. Previously presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO).

Nastaoupil LJ, Sinha R, Byrtek M, Zhou X, Taylor M, Friedberg J, Link B, Cerhan J, Dawson K, Flowers C. Characteristics and effectiveness of rituximab (R) maintenance regimens among US patients diagnosed with follicular lymphoma (FL) 2004-2007. Poster presented at the 17th Congress of the European Hematology Association; June 14, 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jul 16; 97(s1):95-6. Previously presented at the 53rd Annual Meeting of the American Society of Hematology.

McKenna S, Twiss J, Wilburn J, Crawford S, Loth K. Investigation of the impact of MDS from the patients' perspective. Poster presented at the 17th Congress of the European Hematology Association; June 2012. Amsterdam, The Netherlands. [abstract] Haematologica. 2012 Jun; 97(S1):357-8.

Blum JL, Kohles J, McKenna E, Scotto N, Hu S, Odom D, Kaye JA, Glück S. Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials. Breast Cancer Res Treat. 2011 Jan 1;125(2):431-9.

Hooper SR, Roberts JE, Nelson LM, Zeisel S, Kasambira D. Preschool predictors of narrative writing skills in elementary school children. Sch Psychol Q. 2010 Mar;25(1):1-12.

Zhou X, Cella D, Cameron D, Amonkar MM, Segreti A, Stein S, Walker M, Geyer CE. Lapatinib plus capecitabine versus capecitabine alone for HER2+(ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Res Treat. 2009 Oct 1;117(3):577-89. doi: 10.1007/s10549-009-0310-8

Ball EV, Stenson PD, Abeysinghe SS, Krawczak M, Cooper DN, Chuzhanova NA. Microdeletions and microinsertions causing human genetic disease: common mechanisms of mutagenesis and the role of local DNA sequence complexity. Hum Mutat. 2005 Sep;26(3):205-13. doi: 10.1002/humu.20212

Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional assessment of cancer therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr 1;90(3):295-8.

Abeysinghe SS, Stenson PD PD, Krawczak M, Cooper DN DN. Gross Rearrangement Breakpoint Database (GRABDTM). Hum Mutat. 2004;23(3):219-21.

Abeysinghe SS, Chuzhanova N, Krawczak M, Ball EV, Cooper DN. Translocation and gross deletion breakpoints in human inherited disease and cancer I: nucleotide composition and recombination-associated motifs. Hum Mutat. 2003 Sep;22(3):229-44.

Chuzhanova N, Abeysinghe SS, Krawczak M, Cooper DN. Translocation and gross deletion breakpoints in human inherited disease and cancer II: potential involvement of repetitive sequence elements in secondary structure formation between DNA ends. Hum Mutat. 2003 Sep;22(3):245-51.

Stenson P, Ball EV, Mort M, Phillips A, Shiel J, Thomas N, Abeysinghe SS. Human Gene Mutation Database (HGMD). Hum Mutat. 2003;(21):577-81.

Krawczak M, Ball EV, Fenton I, Stenson PD, Abeysinghe SS, Thomas N, Cooper DN. Human gene mutation database-a biomedical information and research resource. Hum Mutat. 2000;15(1):45-51.